Skip to main content
OpenTrials

Clinical trial condition

Hypergammaglobulinemia

Explore clinical trials studying Hypergammaglobulinemia. Study availability and eligibility vary by location and protocol.

136 public trials 35 recruiting studies
Refine in advanced search Browse all conditions

Hypergammaglobulinemia trial results

Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

NCT05469893

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Oregon Health & Science University Portland, Oregon, United States
View Trial Details
Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

NCT06140524

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Johns Hopkins Hospital Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Michigan Health Ann Arbor, Michigan, United States
  • NYU Langone Health Perlmutter Cancer Center New York, United States
View all 39 locations
View Trial Details
Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

NCT03937635

Conditions
Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 747 locations
View Trial Details
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

NCT02269592

Conditions
B-cell Malignancy, Low-grade, Blood Protein Disorders, Bone Marrow Diseases, +36 more
Locations
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Dana Farber Cancer Institute at St. Elizabeth's Brighton, Massachusetts, United States
  • Dana Farber Cancer Institute at Merrimack Valley Methuen, Massachusetts, United States
  • Dana Farber Cancer Institute at Milford Regional Medical Center Milford, Massachusetts, United States
View Trial Details

Related conditions